Biohit

2.79

EUR

+1.45 %

4,845 following

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Investor consensus

Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.

Market cap

42.37M EUR

Turnover

5.24K EUR

P/E (adj.) (25e)

18.6

EV/EBIT (adj.) (25e)

13.51

P/B (25e)

2.91

EV/S (25e)

2.01

Dividend yield-% (25e)

1.34 %

Coverage

Recommendation

Accumulate

Target price

3.20 EUR

Updated

02.03.2025

Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 03.03.2025

Latest extensive report

Released: 15.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

6.8

2025

Interim report Q2'25

Risk

Business risk

Valuation risk

Low

High

All

Research

Press releases

ShowingAll content types

Regulatory press release6/5/2025, 3:00 PM

Constitutive meeting of Biohit Oyj’s Board of Directors

Regulatory press release6/4/2025, 3:00 PM

Decisions of the Annual General Meeting of Biohit Oyj

Press release5/12/2025, 11:00 AM

Clinical validation study of Biohit’s GastroPanel® quick test completed in India

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release5/7/2025, 11:00 AM

Notice of Biohit Oyj’s Annual General Meeting

Regulatory press release3/25/2025, 10:10 AM

Biohit Plc - Managers' transactions - Hendolin

Regulatory press release3/19/2025, 7:30 AM

Publication of Biohit Oyj Annual Report 2024

Regulatory press release3/19/2025, 7:30 AM

Publication of Biohit Oyj Remuneration Report 2024

Regulatory press release3/13/2025, 1:32 PM

Biohit Oyj - Managers' Transactions

Biohit: Safety margin available again

Research3/3/2025, 9:15 AM by

Biohit: Safety margin available again

Biohit's share price has fallen and the risk/reward ratio has become attractive again.

Biohit H2'24: Progress despite a bumpy road

Research2/13/2025, 7:41 AM by

Biohit H2'24: Progress despite a bumpy road

Biohit's figures were already largely known based on preliminary data and the H2 report was in line with expectations.

Regulatory press release2/12/2025, 7:30 AM

BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2024

Biohit H2’24 preview: Growth subdued in H2, but profitability excellent

Analyst Comment2/11/2025, 7:13 AM by

Biohit H2’24 preview: Growth subdued in H2, but profitability excellent

Based on releases in recent months, we expect growth from the launch of the new product, distribution partnerships and a new market opening around the middle of the year, referred to by the company in its Q3’24 IR blog.

Press release2/6/2025, 9:00 AM

BIOHIT and Restalyst announce collaboration to improve non-invasive early gastric cancer detection

Press release1/31/2025, 9:30 AM

BIOHIT introduces the FAEX™ Sample System for stool sample collection and handling

Analyst Comment1/17/2025, 7:07 AM by

New distribution rights for Biohit

Biohit announced on Thursday that it has signed a distribution agreement with Biomedal for the distribution of celiac disease diagnostic tests in selected European countries.

Press release1/16/2025, 9:00 AM

BIOHIT secures European distribution rights for Biomedal’s gluten immunogenic peptide tests

Extensive research1/15/2025, 12:56 PM by

Biohit extensive report: Profitable growth through diagnostics

Biohit has achieved a successful turnaround and is targeting strong growth of 15-20% over the 2024-28 strategy period. We expect the company's earnings to continue to grow in the coming years, supported by the development of new markets and new product launches.

Analyst Comment1/9/2025, 6:53 AM by

Biohit test receives further proof of its effectiveness in the UK

Biohit announced on Wednesday the results of a study of GastroPanel® for the diagnosis of gastric precancerous conditions. The GastroPanel® test on a blood sample identified patients at risk of gastric cancer requiring further examinations with over 90% accuracy.

Press release1/8/2025, 8:30 AM

Approval of Biohit’s GastroPanel® test for use by the British National Health Service (NHS) takes a major step forward

Research12/23/2024, 6:50 AM by

Biohit: Performance surprised positively

Biohit issued a profit warning related to revenue, but despite this, the new 2024 earnings guidance (EBIT percentage 16-18%) clearly exceeded our expectations.

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.